Drug Trial Radar · NCT05812781
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome
Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Mar 18, 2023
Primary completion
Mar 6, 2024
Study completion Mar 6, 2024
Sponsor
- Lead sponsor
- Zomagen Biosciences Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B. The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period. The maximum length of treatment is 4 weeks.
Conditions
- Cryopyrin Associated Periodic Syndrome
Interventions
VTX2735Drug
Dose A
VTX2735Drug
Dose B
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of VTX2735Time frame: From the initial administration of VTX2735 through study completion, up to 10 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Local Site # 222
San Diego, California
Local Site # 223
Columbus, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.